Summary Top of page Summary Introduction Extracellular vesicles produced by stem cells What we have learned from mature liver cell transplantation in humans? MSCs in human clinical applications Disclosure of Conflict of Interests References
Hemophilia remains a non-curative disease, and patients are constrained to undergo repeated injections of clotting factors. In contrast, the sustained production of endogenous factors VIII (FVIII) or IX (FIX) by the patient's own cells could represent a curative treatment. Gene therapy has thus provided new hope for these patients. However, the issues surrounding the durability of expression and immune responses against gene transfer vectors remain. Cell therapy, involving stem cells expanded invitro, can provide de novo protein synthesis and, if implanted successfully, could induce a steady-state production of low quantities of factors, which may keep the patient above the level required to prevent spontaneous bleeding. Liver-derived stem cells are already being assessed in clinical trials for inborn errors of metabolism and, in view of their capacity to produce FVIII and FIX in cell culture, they are now also being considered for clinical application in hemophilia patients.
Hemophilia A is the most common severe inherited bleeding disorder, affecting 1 in 5000 male births. This pathology exhibits different phenotypic expressions depending on its associated factor VIII (FVIII) plasma levels, resulting in severe (<1%), moderate (15%), or mild (630%) forms of expression [1]. This disease originates from an inherited deficiency or dysfunction in the procoagulant FVIII, a crucial element of the intrinsic pathway of blood coagulation involved in the conversion of factor X to Xa [2]. In severe cases, FVIII deficiency leads to spontaneous bleeding and internal hemorrhage that can cause disability and even death, if left untreated [3].
There is currently no cure for hemophilia A. The rationale behind replacement treatment is to sufficiently increase concentrations of the missing factor to arrest spontaneous and traumatic bleeds. Plasma-derived products became available in the 1970s, proving effective in controlling bleeding episodes through the development of home-therapy programs. However, concentrates derived from pooled plasma were contaminated with HIV and the hepatitis B or C virus, causing post-transfusion hepatitis and immunodeficiency in almost all hemophilia patients who received these concentrates. In 1984, the FVIII gene was successfully cloned, enabling the production of recombinant human FVIII (rFVIII) using mammalian cell cultures, and the first rFVIII went on the market in 1992 [4].
The introduction of rFVIII revolutionized hemophilia patient management by providing an effective and safe treatment of bleeding episodes. Nevertheless, there remain several issues concerning FVIII replacement therapy that have yet to be resolved. The primary complications are as follows: the short half-life of replacement products, necessitating frequent intravenous infusions; the immunogenicity of FVIII concentrates; and the affordability and availability of FVIII products [5].
During the last decades, several attempts have been made to develop a long-term cure, such as gene and cell therapy. Hemophilia A is a perfect candidate for gene therapy, given its monogenetic nature that can potentially be cured by continuous endogenous FVIII expression. For hemophilia treatment, by increasing circulating clotting factor levels to above 1% of normal, it may be possible to obtain a prophylactic therapeutic effect, thereby reducing risks of both mortality and morbidity.
If gene therapy is able to slightly increase clotting factor levels, it could significantly improve the clinical phenotype [6]. Recently, hemophilia B gene therapy has achieved promising outcomes in human clinical trials [7]. A key advantage of the development of gene therapy strategies for hemophilia B is the relatively small size of the cDNA of FIX, measuring approximately 1.4 kB of the coding sequence. This renders it amenable to insertion into different gene transfer vectors and enables the addition of numerous transcriptional regulatory elements to both improve and restrict transgene expression in selected cell types. The cDNA of FVIIIis much larger than that ofFIX (>8kB) and cannot be as readily accommodated in gene transfer vectors. Several strategies have previously been attempted to overcome this difficulty, by either deleting the B-domain or using two viral vectors [8].
Moreover, the main complication of viral vector delivery of clotting factor transgenes is the host immune responses [9]. A pre-existing immune response against capsid proteins is one of the criteria excluding hemophilia patients from gene therapy. Approximately 40% of the adult human population possess neutralizing antibodies against the adeno-associated virus (AAV)-2 [10], and these antibodies can cross-neutralize other AAV serotypes. In addition, patients receiving systemic viral vector administration develop a postgene therapy immune response. This response was shown to be associated with the destruction of cells expressing viral proteins after transduction, thereby decreasing the gene transfer's efficacy, along with the development of neutralizing antibodies against the viral vector employed as therapeutic agent, therefore preventing the possibility of vector re-administration.
Orthotopic liver transplantation has proven effective in correcting the hemophilic phenotype in hemophilia patients with decompensated hepatitis C (HCV)-cirrhosis [11]. This suggests that the liver plays a central role in producing blood-clotting factors like FVIII. The hepatic cellular compartments that produce FVIII are primarily composed of liver sinusoidal endothelial cells (LSEC) [12, 13], although earlier evidence has suggested hepatocytes to be instrumental in FVIII expression [14]. Transplanting such cells that are capable of releasing FVIII insitu or into the circulation is an attractive approach for treating clotting factor disorders. Notably, in murine endothelial cell cultures, FVIII production was measured to amount to 0.07IUmillion1 cellsday1. If we extrapolate this to the 81010 liver endothelial cells contained in an adult human liver, the production would cover more than that required by a human adult [15]. Transplanting 2106 mature LSECs, representing 10% of their endothelial compartment, via the portal vein in hemophilia A mice was shown to restore plasma FVIII activity levels to 14%25% of normal, thereby correcting spontaneous bleeding [16].
In addition to endothelial cells, mesenchymal stem cells (MSCs) are also able to secrete FVIII in the cell culture supernatant, which makes them attractive candidates for treating hemophilia. MSCs are increasingly used in several medical areas for repairing organs, such as the heart, bone, cartilage, and liver. These are tissue-resident cells that can be obtained from different tissues and organs, exhibiting the propensity to attach onto surfaces and proliferate invitro. In certain conditions, they differentiate into mature cells, such as bone, cartilage, and adipocyte- or hepatocyte-like cells. These cells express specific surface markers,
such as CD90 and CD105, and are negative for hematopoietic markers like CD45 [17]. However, MSC from different tissues may differ by other characteristics. For example, unmodified MSCs from human liver and lungs produce FVIII in the culture supernatant in much higher quantities compared to human bone marrow-derived MSCs (1.2 and 1.7% vs. 0.12%, respectively, per 105 cells at the 48-h time point) [18].
Go here to read the rest:
Mesenchymal stem cell treatment for hemophilia: a review ...
- More Stem Cells Extracted For Later Use For My MS - March 14th, 2011 [March 14th, 2011]
- Stem Cell Institute Panama City Panama - April 1st, 2011 [April 1st, 2011]
- Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science - April 8th, 2011 [April 8th, 2011]
- Macular Degeneration Improved With Stem Cells - April 8th, 2011 [April 8th, 2011]
- Stem Cell Therapy for Kidney Failure - April 15th, 2011 [April 15th, 2011]
- SIRA: Could Stem Cell Therapy Renew Your Body Cells? - April 22nd, 2011 [April 22nd, 2011]
- Stem Cell Therapy for Autism - May 20th, 2011 [May 20th, 2011]
- Stem Cell Therapy for Critical Limb Ischemia - May 21st, 2011 [May 21st, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv - May 21st, 2011 [May 21st, 2011]
- Stem Cell Therapy Success - May 21st, 2011 [May 21st, 2011]
- Doctors Use Stem Cells to Grow New Windpipes - May 21st, 2011 [May 21st, 2011]
- Dog Undergoes Stem Cell Therapy - May 23rd, 2011 [May 23rd, 2011]
- Stem Cell Therapy for Multiple Sclerosis - May 23rd, 2011 [May 23rd, 2011]
- Dogs now getting stem cell therapy - May 24th, 2011 [May 24th, 2011]
- Stem Cell Therapy for Rheumatoid Arthritis - May 30th, 2011 [May 30th, 2011]
- Stem Cell Therapy for Type II Diabetes - May 31st, 2011 [May 31st, 2011]
- Stem Cell Therapy for Cerebral Palsy - May 31st, 2011 [May 31st, 2011]
- Visions Episode 92: Stem Cells Discovery - May 31st, 2011 [May 31st, 2011]
- Stem Cell Therapy For Alzheimer's/Dementia - June 1st, 2011 [June 1st, 2011]
- Stem Cell Patient Richard H. MS Treatment - June 10th, 2011 [June 10th, 2011]
- Stem Cell Therapy Injections - June 12th, 2011 [June 12th, 2011]
- Stem Cells Used to Grow Windpipes - June 20th, 2011 [June 20th, 2011]
- Stem Cell Therapy for Stroke - Gary Steinberg, Stanford University - June 21st, 2011 [June 21st, 2011]
- Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Approach - June 23rd, 2011 [June 23rd, 2011]
- Stem Cell Therapy Cream: Less Wrinkles In 30 Days or Less Anti-Wrinkle Cream That Works - June 26th, 2011 [June 26th, 2011]
- Stem Cell Therapy for Spinal Cord Injury - Injured Airline Pilot Flies Again - June 27th, 2011 [June 27th, 2011]
- Clinical Advances in Adult Stem Cell Therapy: Dr. Jorge Paz - June 27th, 2011 [June 27th, 2011]
- Stem Cell Injection Treatment - Stem Cell Therapy - June 27th, 2011 [June 27th, 2011]
- Stem Cell Therapy MS: Sam Harrell and The Superbowl - June 27th, 2011 [June 27th, 2011]
- Documentary: Stem Cell Therapy for Muscular Dystrophy - Ryan Benton's Story - June 30th, 2011 [June 30th, 2011]
- Stem Cell Therapy--Hillcrest Animal Hospital - July 14th, 2011 [July 14th, 2011]
- WAVE3 News Adipose Stem Cell Therapy - July 20th, 2011 [July 20th, 2011]
- Lou Gehrig's Disease (ALS): Stem Cell Therapy - A Patient's Perspective - July 23rd, 2011 [July 23rd, 2011]
- University of Melbourne announce Stem Cells Discovery - July 28th, 2011 [July 28th, 2011]
- Stem Cell Therapy (Regenerative Medicine) in New Jersey - August 9th, 2011 [August 9th, 2011]
- Spinal Cord Injury - Stem Cell Therapy - August 9th, 2011 [August 9th, 2011]
- Dr. Craig Saunders Adult Stem Cell Therapy - August 9th, 2011 [August 9th, 2011]
- Embryonic stem cell therapy in China (www.esctherapy.com) - August 13th, 2011 [August 13th, 2011]
- Mesenchymal stem cells and marrow stromal cells - August 15th, 2011 [August 15th, 2011]
- Mesenchymal Stem Cells in Regenerative Medicine: Of Hopes and Challenges - August 15th, 2011 [August 15th, 2011]
- Cardiomyogenic differentiation of Mesenchymal Stem cells (KUM2/9-15c) - August 15th, 2011 [August 15th, 2011]
- SENS4 - Engineered Mesenchymal Stem Cells - The Road to Skeletal Tissue Regeneration (1/3) - August 15th, 2011 [August 15th, 2011]
- Mesenchymal stem cells and marrow stromal cells---2nd--- - August 15th, 2011 [August 15th, 2011]
- Cadiomyogenesis of human mesenchymal stem cells - August 15th, 2011 [August 15th, 2011]
- Mesenchymal Stem Cells Transplantation In Heart.wmv - August 15th, 2011 [August 15th, 2011]
- Ying Liu discusses IPS cell therapy for ALS - August 15th, 2011 [August 15th, 2011]
- Non-controversial Stem Cells: Rationale for Clinical Use: Neil Riordan, Ph.D. - Miami, FL - August 16th, 2011 [August 16th, 2011]
- From Surgical Repair to Stem Cell Repair: A Surgeon's Journey by Leonard Smith MD, FACS - August 16th, 2011 [August 16th, 2011]
- Bone Marrow Aspiration - Stem Cell Therapy - August 16th, 2011 [August 16th, 2011]
- Non-controversial Stem Cells: Rationale for Clinical Use - Dr. Neil Riordan - August 16th, 2011 [August 16th, 2011]
- TEDxSingapore - Susan Lim - Hype and hope of stem cell research - August 16th, 2011 [August 16th, 2011]
- Cryo-Lip Instruction Video.VOB.flv - August 16th, 2011 [August 16th, 2011]
- Stem Cells Repair Damaged Heart [7-07-2011] - August 16th, 2011 [August 16th, 2011]
- Andalusian Stem Cell Bank - August 16th, 2011 [August 16th, 2011]
- Adult Stem Cell Therapy Clinical Advances - Dr. Jorge Paz in San Diego, CA March 2011 - August 16th, 2011 [August 16th, 2011]
- Mesenchymal Stem Cells Drive New MS Study/Treatment - August 26th, 2011 [August 26th, 2011]
- Sims 2 Mafia Story Part 7 - Farewell, Godfather/Stem Cell Medicine - August 28th, 2011 [August 28th, 2011]
- STEM CELLS - Mesenchymal Stem Cells (Balzitt).flv - August 30th, 2011 [August 30th, 2011]
- Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550 - September 3rd, 2011 [September 3rd, 2011]
- Stem Cell Research: Huntington's Disease - September 5th, 2011 [September 5th, 2011]
- Autism Stem Cell Trip - September 6th, 2011 [September 6th, 2011]
- Before/After Stem Cell for COPD: From Unable to Walk, to Dancing at My Daughter's Wedding - September 6th, 2011 [September 6th, 2011]
- Regenerative Medicine with Placenta Extracts and Stem Cell Therapies - Dr. Janethy Balakrishnan - September 6th, 2011 [September 6th, 2011]
- Stem Cells - September 6th, 2011 [September 6th, 2011]
- The Politics and Promise of Stem Cell Research - September 6th, 2011 [September 6th, 2011]
- Stem cell therapy in Guatemala - (closer than China) - September 7th, 2011 [September 7th, 2011]
- Stem Cell Therapy for Cerebral Palsy - Holly Catalano - September 9th, 2011 [September 9th, 2011]
- Clinical Advances in Adult Stem Cell Therapy - Dr. Jorge Paz Rodriguez (Miami) - September 9th, 2011 [September 9th, 2011]
- CryoLip Stem Cell Preservation - September 20th, 2011 [September 20th, 2011]
- Dr. Gonzalez tells his story of Stem Cell Treatment and Stem Cell Therapy - September 23rd, 2011 [September 23rd, 2011]
- A Three Minute Cell Passage - September 23rd, 2011 [September 23rd, 2011]
- Bone Marrow - Stem Cell Prolotherapy - September 23rd, 2011 [September 23rd, 2011]
- Stem Cell Therapy- Interview with Indian Surgeon - September 23rd, 2011 [September 23rd, 2011]
- Cryo-Lip.f4v - September 23rd, 2011 [September 23rd, 2011]
- CryoCord Corporate Video (2 Mins) - September 23rd, 2011 [September 23rd, 2011]
- SENS4 - Engineered Mesenchymal Stem Cells - The Road to Skeletal Tissue Regeneration (3/3) - September 23rd, 2011 [September 23rd, 2011]
- What are stem cells? - September 24th, 2011 [September 24th, 2011]
- Dental stem cell bank in Hyderabad - September 24th, 2011 [September 24th, 2011]
- Stem Cell Therapeutics: Tissue Regeneration - Christopher J. Centeno, MD - September 25th, 2011 [September 25th, 2011]
- Stem Cell Types and Sources - September 25th, 2011 [September 25th, 2011]